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likely to have negative inotropic effects compared with esmolol. 9, 10 Although there have been several studies that support the efficacy of landiolol, 11-13 a large-scale multicenter randomized clinical trial has not been performed to assess the efficacy of landiolol for patients with postoperative AF after open heart surgery.
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The aim of the present prospective, randomized, open-label trial in patients with AF or atrial flutter (AFl) after open heart surgery was therefore to compare the efficacy and safety of landiolol to diltiazem for postoperative AF or AFl.
Methods

Study Design and Subjects
A prospective, multicenter, randomized, open-label study of i.v. landiolol vs. i.v. diltiazem in patients with postoperative AF or AFl (Japan Landiolol kick-off of novel investigation for gold standard heart study [JL-KNIGHT study]) was undertaken at 36 hospitals in Japan between January 2008 and June 2009. Patients between 20 and 85 years of age who were undergoing elective open heart surgery were eligible for inclusion. The steering committee initially planned to enroll 400 patients in the study, based on the following considerations. If the frequency of conversion to sinus rhythm after 8 h of treatment with landiolol or diltiazem is 60% and 25%, respectively, the number of subjects required would be 30 for each group based on the Mooss et al data. 8 Considering dropout and withdrawal during the study, 40 patients would be needed for each group. Consequently, we estimated that the total number of subjects should be 400, assuming that the frequency of AF after open heart surgery is 20%. Exclusion criteria were acute myocardial infarction within 3 days; history of supraventricular arrhythmia that had required treatment; sinus node disease; permanent pacemaker; severe heart failure (New York Heart Association III/IV or ejection fraction <35%); atrioventricular block (AV block; ≥second degree); contraindications to either β-blocker or calcium channel blocker therapy; AF with a known secondary cause (eg, electrolyte imbalance, Wolff-Parkinson-White syndrome, or hyperthyroidism); hypotension (<90/60 mmHg); and perioperative use of an anti-arrhythmic agent other than digitalis.
All patients provided written informed consent to this study after admission to hospital. The study protocol was approved by the institutional review boards and ethics committees of all participating hospitals, and the study was performed in accordance with the Declaration of Helsinki.
Study Protocol
When patients were enrolled in this study, one of the 2 study drugs was randomly assigned at the participating institution using the envelope method. Patients were continuously monitored on telemetry for up to 1 week after surgery. A study drug was given if postoperative AF/AFl occurred with a ventricular rate ≥100 beats/min for 5 min. Landiolol was given as a continuous infusion at an initial rate of 0.5-2 μg · kg -1 · min -1 that was titrated to a maximum rate of 40 μg · kg -1 · min -1 (reassessed every 10 min) based on hemodynamic or electrocardiographic responses. Diltiazem was given as a bolus dose of 0.25 mg/kg over 2 min, followed by an initial rate of 3 mg/h that was titrated to a maximum rate of 15 mg/h (reassessed at approximately 1-h intervals) based on hemodynamic or electrocardiographic responses at the investigator's discretion. The maintenance infusion of either drug was titrated upward to control the ventricular rate at <90 beats/min. Patients all received the study drugs following the onset of AF/AFl and had a treatment duration of 24 h. If hypotension (systolic blood pressure <90 mmHg) or bradycardia (heart rate <50 beats/min) occurred, the dose was down-titrated or infusion of the drug was discontinued until symptoms resolved.
The primary endpoint was frequency of conversion to sinus rhythm after 8 h of treatment. The secondary endpoints were (1) frequency of conversion to sinus rhythm after 24 h of treatment and (2) achievement of rate control (<90 beats/min).
Accordingly, the total number of treated patients who were converted to sinus rhythm or who achieved the target heart rate after 8 h and 24 h of study drug infusion was determined, and blood pressure and heart rate data were collected every 1 h following initiation of therapy. Patients were assessed for adverse reactions including AV block, bronchospasm, asystole, bradycardia, and hypotension. When AF/AFl was converted to sinus rhythm, the patient was monitored on telemetry for 3 days after the discontinuation of the drug to detect the recurrence of arrhythmia.
Statistical Analysis
Continuous variables are expressed as mean ± SD. Clinical characteristics of the 2 groups were compared using an independent t-test for continuous variables and with either Fisher's exact test or a chi-square test for categorical variables. Differences of conversion rates, the percentage of patients achieving rate control, and adverse events were analyzed with Fisher's exact test or the chi-square test as appropriate. In all analyses, P<0.05 was considered statistically significant.
Results
A total of 420 patients from 36 hospitals participated in the study. Among them, 82 patients (19.5%) developed postoperative AF and received one of the study drugs. In all patients, AFl was not observed perioperatively. Eighty-five patients were excluded because of missing data or lack of adherence to the study protocol, therefore 335 patients were included in the final analysis. Among them, 71 patients (21.2%) developed postoperative AF and received either landiolol (n=35) or diltiazem (n=36; Figure) . The clinical characteristics of the 2 study groups were similar ( Table 1) .
A higher conversion rate to sinus rhythm after 8 h of treatment was obtained in the landiolol group (54.3%) than the diltiazem group (30.6%; P<0.05; Table 2 ). In contrast, there was no difference between the landiolol and diltiazem groups with regard to conversion to sinus rhythm after 24 h (74.3% vs. 61.1%, P=NS). When the efficacy of heart rate control (<90 beats/min) was analyzed, there was no difference between the 2 groups after 8 h and 24 h of treatment. Only one of 35 patients in the landiolol group, however, had failure of heart rate control within 72 h of starting treatment, while 8 of 36 patients in the diltiazem group did not achieve heart rate control (P<0.05).
With respect to side-effects, the incidence of hypotension (systolic blood pressure <90 mmHg) was significantly lower in the landiolol group (11.4%; P<0.05) compared with the diltiazem group (30.6%; Table 3 ). In addition, 4 patients receiving diltiazem experienced bradycardia that required treatment, vs. no patients from the landiolol group (P<0.05). The length of intensive care unit stay, however, did not differ between the 2 groups (landiolol, 3.9±2.1 days; diltiazem, 3 
.4±1.2 days; NS). Landiolol vs. Diltiazem for Postoperative AF
Discussion
There were 2 main findings of this study. First, landiolol was more effective compared with diltiazem for conversion of AF to sinus rhythm within 8 h of starting treatment. Second, landiolol treatment for postoperative AF was associated with a lower incidence of side-effects such as hypotension or bra- Pre-infusion HR (beats/min) 129±20 131±20
Pre-infusion BP (mmHg) 116±26/62±14 112±17/62±13
Data given as mean ± SD or n. CABG, coronary artery bypass grafting; VR, valve replacement; HR, heart rate; BP, blood pressure. Data given as n (%). *P<0.05 vs. diltiazem ( χ2 -test). HR, heart rate; AF, atrial fibrillation. dycardia compared with diltiazem. Although it is still not clear whether the same mechanisms leading to AF in the general population are responsible for the onset of postoperative AF, current evidence suggests that its pathogenesis is multifactorial. The inflammatory response and oxidative stress associated with cardiopulmonary bypass, cardiotomy, and ischemia-reperfusion injury can induce further myocardial damage and are arrhythmogenic, which may lead to the onset of AF in patients with a susceptible anatomical substrate. Moreover, excessive sympathetic activity or suppression of parasympathetic activity can promote the onset and persistence of AF. 14 It is well known that sympathetic hyperactivity and high circulating catecholamine levels occur after cardiac surgery. Increased sympathetic activation provokes ectopic impulses, inflammation, increased vascular permeability, and altered atrial refractoriness, contributing to the creation of an arrhythmogenic substrate. 15 In the present study, landiolol was more effective for achieving conversion to sinus rhythm than diltiazem, which suggests that controlling excessive sympathetic activity may be important in the treatment of postoperative AF.
The present results for landiolol seem to be similar to those for esmolol at first assessment, but are not. Regarding the effect of esmolol vs. calcium antagonists (verapamil or diltiazem) for postoperative AF: (1) esmolol was superior to calcium antagonists in the conversion rate 8, 16 and did not inhibit spontaneous conversion; 17 (2) there was no difference of heart rate control or the incidence of side-effects between esmolol and calcium antagonists; 7,8 and (3) intraoperative use of esmolol for heart rate control may worsen cardiac performance, as indicated by an increase of pulmonary arterial pressure or pulmonary vascular resistance. 18 In contrast, the present study showed that landiolol treatment led to a significantly higher rate of conversion than diltiazem treatment during the initial 8 h of therapy and that only one of 35 patients in the landiolol group had inadequate heart rate control during the 72-h observation period following the start of treatment. Landiolol, however, caused a lower incidence of side-effects such as bradycardia and hypotension compared with diltiazem, so these results differed from the data obtained for esmolol and calcium antagonists. 7, 8 One explanation for the disparity between esmolol and landiolol is that landiolol is a potent shortacting and more β1-selective blocker than esmolol. Another is that landiolol exerts a clinically relevant negative chronotropic action without any associated negative inotropic action, thus having fewer negative inotropic side-effects compared with esmolol. 9,10 Therefore, landiolol may be superior to esmolol with respect to the suppression of cardiovascular events, although we did not compare these drugs in the present study. We used low-dose infusion of landiolol at a similar level as in other studies to minimize the incidence of sideeffects. Fujiwara et al reported that low-dose infusion (1.5-2.5 μg · kg -1 · min -1 ) of landiolol for 2 days after CABG is effective and sufficient for preventing AF without suppressing cardiac function. 13 Sezai et al reported that infusion of landiolol at 2 μg · kg -1 · min -1 from the time of central anastomosis during CABG and for 2 days subsequently was more effective for preventing AF than placebo and was associated with a lower incidence of major complications. 19 The incidence of side-effect in these studies was similar to that in the present study.
In the present study, infusion of the ultra-short-acting β1-blocker landiolol (t1/2=4 min) for only 24 h maintained heart rate control for 48 h after the cessation of treatment, and 24-h infusion of landiolol had a similar suppressant effect to diltiazem on the recurrence of AF. It is possible that control of sympathetic activity at the time close to the onset of AF may be important for treating tachycardiac AF, but the mechanism involved is still unclear. Also, the optimum timing and duration of landiolol infusion need to be determined in the future.
In addition to treatment of AF, it is also important to prevent postoperative AF. 6 Several drugs, such as amiodarone and sotalol, have shown efficacy in preventing postoperative AF, but these agents need to be started several days before surgery and have the potential to cause significant adverse effects that include hypotension, bradycardia, and severe ventricular arrhythmias. Because landiolol may be able to prevent the postoperative onset of AF, we plan to start the JL-KNIGHT study II to test the preventive effects of landiolol.
Conclusion
This study showed that landiolol is more effective and safer than diltiazem for patients with postoperative AF after open heart surgery.
